Projects funded by the NCN
Selective inhibitors of γ-aminobutyric acid (GABA) transporter subtype 3 (GAT3) as a new pharmacological tools and a chance for a novel therapy of GABA-related disorders.
2021/41/B/NZ7/02825
Keywords:
medicinal chemistry drug discovery γ-butyric acid γ-aminobutyric acid transporters inhibitors of γ-aminobutyric acid transporters, selective inhibitors of the GAT3-type transporter epilepsy neuropathic pain Alzheimer's disease
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ3_7: Signal transduction
- ST4_8: Organic chemistry
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Jagielloński, Collegium Medicum
woj. małopolskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 11
Call: OPUS 21 - announced on 2021-03-15
Amount awarded: 1 684 200 PLN
Project start date (Y-m-d): 2022-02-07
Project end date (Y-m-d): 2026-02-06
Project duration:: 48 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.